Worldquant Millennium Advisors LLC Has $35.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Worldquant Millennium Advisors LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 156.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 150,191 shares of the biopharmaceutical company's stock after purchasing an additional 91,671 shares during the quarter. Worldquant Millennium Advisors LLC owned about 0.12% of Alnylam Pharmaceuticals worth $35,341,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $33,000. OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Finally, IFP Advisors Inc increased its stake in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.3%

Shares of Alnylam Pharmaceuticals stock traded up $0.96 during trading hours on Monday, hitting $289.96. The company's stock had a trading volume of 757,018 shares, compared to its average volume of 918,662. The company has a market capitalization of $37.81 billion, a PE ratio of -133.62 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a 50 day moving average of $258.36 and a 200 day moving average of $254.19. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ALNY. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.